On Apr. 3, 2020, BD (Becton, Dickinson) and BioGX announced that the U.S. Food and Drug Administration (FDA) had granted Emergency Use Authorization (EUA) for a new diagnostic test that will enable hospitals to screen for COVID-19 (coronavirus) on site and get results in under three hours.

The test will be run on the BD MAX System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state. Each unit is capable of analyzing hundreds of samples per day.